Who
Ronald E. Bruehlman
Director
Company insider
Files Form 4 as: Director, GoodRx Holdings; Officer, IQVIA Holdings; Officer, IMS Health Holdings.
In numbers
- Trades disclosed
- 58
- Buys
- 3
- Sells
- 1
- Bought
- $1.6M
- Sold
- $1,028
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 10 Feb 2015
- Last trade
- 16 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 17 Jun 2026 | GDRX GoodRx HoldingsPayments & Processors | SEC FORM 4 Code A | —73,434 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | GDRX GoodRx HoldingsPayments & Processors | SEC FORM 4 Code A | —73,434 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | GDRX GoodRx HoldingsPayments & Processors | SEC FORM 4 Code A | —4,642 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | GDRX GoodRx HoldingsPayments & Processors | SEC FORM 4 Code A | —4,642 at $0.00 | filing |
| 8 Feb 2026filed 10 Feb 2026 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code A | —16,335 at $0.00 | filing |
| 8 Feb 2026filed 10 Feb 2026 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code F | $1.3M6,801 at $187.49 | filing |
| 8 Feb 2026filed 10 Feb 2026 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code A | —16,335 at $0.00 | filing |
| 8 Feb 2026filed 10 Feb 2026 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code F | $1.3M6,801 at $187.49 | filing |
| 1 Jan 2026filed 5 Jan 2026 | GDRX GoodRx HoldingsPayments & Processors | SEC FORM 4 Code A | —18,251 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | GDRX GoodRx HoldingsPayments & Processors | SEC FORM 4 Code A | —18,251 at $0.00 | filing |
| 8 Nov 2025filed 10 Nov 2025 | GDRX GoodRx Holdingsoption or derivative · Payments & Processors | SEC FORM 4 Code M | —21,691 at $0.00 | filing |
| 8 Nov 2025filed 10 Nov 2025 | GDRX GoodRx HoldingsPayments & Processors | SEC FORM 4 Code M | —21,691 | filing |
| 3 Jun 2025filed 4 Jun 2025 | GDRX GoodRx HoldingsPayments & Processors | SEC FORM 4 Code A | —57,050 at $0.00 | filing |
| 10 Feb 2025filed 12 Feb 2025 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code F | $188K907 at $206.97 | filing |
| 28 Jan 2025filed 30 Jan 2025 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | —31,603 at $0.00 | filing |
| 28 Jan 2025filed 30 Jan 2025 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code A | —6,286 at $0.00 | filing |
| 28 Jan 2025filed 30 Jan 2025 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code F | $448K2,201 at $203.43 | filing |
| 1 Jan 2025filed 3 Jan 2025 | GDRX GoodRx HoldingsPayments & Processors | SEC FORM 4 Code A | —10,653 at $0.00 | filing |
| 8 Nov 2024filed 12 Nov 2024 | GDRX GoodRx Holdingsoption or derivative · Payments & Processors | SEC FORM 4 Code A | —65,075 at $0.00 | filing |
| 8 Nov 2024filed 12 Nov 2024 | GDRX GoodRx HoldingsPayments & Processors | SEC FORM 4 Code A | —1,128 at $0.00 | filing |
News
IQVIA (NYSE:IQV) Given New $303.00 Price Target at Stifel NicolausIQV · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Ronald E. Bruehlman; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.